Jackson G. Schumacher

Jackson G. Schumacher

Auto-generated profile, based on publicly available information

Jackson G. Schumacher

Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02129, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2025 in EBioMedicine
Verified
Journal Article
Open access
JSJackson G. Schumacher
Jackson G. Schumacher
XZXinyuan Zhang
Xinyuan Zhang
EMEric A. Macklin
Eric A. Macklin
JWJian Wang
Jian Wang
ABArmin Bayati
Armin Bayati
XCXiqun Chen
Xiqun Chen
α-Synuclein (α-syn) seed amplification assays (SAAs) have shown remarkable potential in diagnosing Parkinson's disease (PD). Using data from the Parkinson's Progression Markers Initiative (PPMI) cohort, we aimed to test whether baseline α-syn seeding activity and α-syn SAA kinetic parameters are associated with disease progression in sporadic PD, LRRK2-associated PD (LRRK2 PD), and GBA-associated PD (GBA PD). We analysed 7 years of motor, non-motor, and cognitive assessments and 5 years of dopamine transporter imaging along with baseline α-syn SAA results from 564 PPMI participants (n = 332 sporadic PD, 162 LRRK2 PD, and 70 GBA PD) using linear mixed-effects models, adjusted for potential confounders, to test whether baseline α-syn SAA positivity (n = 315 sporadic PD, 111 LRRK2 PD, and 66 GBA PD) and α-syn SAA kinetic parameters are associated with PD progression. While non-statistically significant, there was a trend towards faster motor decline in participants with α-syn SAA positive LRRK2 PD compared to those with α-syn SAA negative LRRK2 PD (MDS-UPDRS III points per year: 2.39 (95% confidence interval: 1.86-2.92) vs. 1.76 (0.93-2.60); difference = 0.63 (-0.29 to 1.55, p = 0.18). This trend appeared to be driven by R1441C/G + M1646T carriers (3.89 (1.22-6.55) vs. 0.31 (-1.32 to 1.93); difference = 3.58 (0.56-6.60, p = 0.02) and excluding them eliminated any trend (2.33 (1.79-2.86) vs. 2.26 (1.34-3.18); difference = 0.07 (-0.93 to 1.07, p = 0.89). Based on a clinically meaningful difference of 4.63 points we found no statistically significant or clinically meaningful difference in motor decline between α-syn SAA positive and α-syn SAA negative participants with sporadic PD (2.46 (2.20-2.72) vs. 2.39 (1.36-3.42); difference = 0.07 (-0.99 to 1.12), p = 0.90) or GBA PD (2.67 (1.91-3.44) vs. 2.40 (-0.18 to 4.99); difference = 0.27 (-2.42 to 2.96), p = 0.84). No statistically significant or clinically meaningful differences were seen in the progression of non-motor symptoms, cognition, or DAT imaging. Additionally, we found no clinically meaningful association between α-syn SAA kinetic parameters and PD progression. We found no statistically significant associations between baseline α-syn seeding activity, α-syn SAA kinetic parameters, and PD progression among manifest patients in the PPMI cohort. Future studies are needed to further investigate relationships among α-syn seeding activity, disease heterogeneity, disease stage, and PD progression. This research was funded by Aligning Science Across Parkinson's grant ASAP-237603 through the Michael J. Fox Foundation for Parkinson's Research and by the National Institutes of Health through the National Institute of Neurological Disorders and Stroke grants R01NS102735 and 5R01NS126260.

27 November 2025 in npj Parkinson's Disease
Verified
Journal Article
Open access
PDF file
RJRoshni Jaffery
Roshni Jaffery
YZYuhang Zhao
Yuhang Zhao
SASarfraz Ahmed
Sarfraz Ahmed
JSJackson G. Schumacher
Jackson G. Schumacher
JAJae Ahn
Jae Ahn
XCXiqun Chen
Xiqun Chen
Mutations in LRRK2 , a leading genetic cause of Parkinson’s disease (PD), are linked to immune dysregulation, but the immune profiles in the periphery and central nervous system (CNS) remain incompletely defined. This study utilized a large cohort of serum samples ( n = 651) and matched CSF samples ( n = 129) from LRRK2 mutation carriers and non-carriers, with and without PD, to assess immune regulators using Luminex immunoassay. After correction for multiple comparisons, LRRK2 mutations were associated with significantly elevated serum levels of SDF-1 alpha and TNF-RII, while CSF markers such as BAFF, CD40L, and IL-27 were nominally reduced. Regardless of LRRK2 status, PD was associated with nominally lower levels of inflammatory analytes in CSF, with minimal changes observed in serum. Correlation analyses revealed distinct immune profiles between serum and CSF, suggesting compartmentalized immune responses. These findings highlight immune alterations in LRRK2 mutation carriers and PD, providing potential serum markers for monitoring immune responses and avenues for mechanistic studies.

1 June 2025 in Journal of Neurophysiology
Verified
Journal Article
Closed access
QWQing Wang
Qing Wang
LALing Aye
Ling Aye
JSJackson G. Schumacher
Jackson G. Schumacher
ASAidan Swan
Aidan Swan
WCWaijiao Cai
Waijiao Cai
KYKai Yang
Kai Yang
Our study identifies reduced angiogenin ( Ang) expression in the ventral midbrain (VMB) of MC1Re/e mice, validated through RNA-seq, RT-qPCR, and Western blot. This CNS-specific downregulation suggests localized regulatory mechanisms linked to neuroprotection and Parkinson’s disease (PD) pathogenesis. Ang’s role in neurodegeneration, angiogenesis, and oxidative stress responses highlights its therapeutic potential in PD. These findings provide critical insights into Ang’s CNS-specific function and underscore the importance of further research into its mechanistic role in PD.

24 March 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
RJRoshni Jaffery
Roshni Jaffery
YZYuhang Zhao
Yuhang Zhao
SASarfraz Ahmed
Sarfraz Ahmed
JSJackson G. Schumacher
Jackson G. Schumacher
JAJae Ahn
Jae Ahn
XCXiqun Chen
Xiqun Chen
Background and Objectives: Mutations in the Leucine-rich repeat kinase 2 ( LRRK2 ) gene are one of the most common genetic causes of Parkinson’s disease (PD) and are linked to immune dysregulation in both the central nervous system and periphery. However, peripheral and central profiles of soluble immune factors associated with LRRK2 mutations and PD have not been comprehensively characterized. Using serum and CSF samples from the LRRK2 Cohort Consortium (LCC), this study aimed to probe a broad range of soluble immune biomarkers associated with LRRK2 mutations and PD. Methods: We investigated the levels of soluble immune regulators in the serum (n=651) and cerebrospinal fluid (CSF, n=129) of LRRK2 mutation carriers and non-carriers, both with and without PD. A total of 65 cytokines, chemokines, growth factors, and soluble receptors were assessed by Luminex immunoassay. A multivariable robust linear model was used to determine levels associated with LRRK2 mutations and PD status, adjusting for age, sex, and sample cohort. Correlations were assessed using the Spearman correlation coefficient. LRRK2 G2019S knock-in mice were used to validate the associations identified in the LCC. Results: In this extensive discovery cohort, we identified several elevated serum immune regulatory factors associated with LRRK2 mutations. In particular, serum stromal cell-derived factor-1 alpha (SDF-1 alpha) levels, as supported by findings in LRRK2 G2019S knock-in mice, and tumor necrosis factor receptor II (TNF-RII) were significantly increased after multiple comparison adjustment. In contrast, LRRK2 mutations were associated with reduced soluble immune markers, including BAFF, CD40-Ligand, I-TAC, MIP-3 alpha, NGF beta, and IL-27 in CSF. Those with clinically diagnosed PD, with or without LRRK2 mutations, did not show strong signals in serum but reduced inflammatory analytes in CSF, including MIF, MMP-1, CD30, Tweak, and SDF-1 alpha. In addition, we found that the serum levels of these soluble immune factors display varied correlations with their corresponding CSF levels. Discussion: This study highlights distinct immune profiles associated with LRRK2 mutations and PD in the periphery and CNS. Serum levels of SDF-1alpha and TNF-RII were elevated in LRRK2 mutation carriers, while CSF immune markers were reduced. In PD, irrespective of LRRK2 status, reduced CSF inflammatory analytes and weak serum signals were observed. These results provide insight into immune dysregulation linked to LRRK2 mutations. If replicable in independent datasets, they offer potential avenues for biomarker and therapeutic exploration.

30 September 2024 in medRxiv
Verified
Preprint
Open access
PDF file
JSJackson G. Schumacher
Jackson G. Schumacher
.Z. Xinyuan Zhang
. Xinyuan Zhang
EMEric A. Macklin
Eric A. Macklin
JWJian Wang
Jian Wang
ABArmin Bayati
Armin Bayati
XCXiqun Chen
Xiqun Chen
Summary: Background: α-Synuclein (α-syn) seed amplification assays (SAAs) have shown remarkable potential in diagnosing Parkinson’s disease (PD). Using data from the Parkinson’s Progression Markers Initiative (PPMI) cohort, we aimed to test whether baseline α-syn seeding activity was associated with disease progression in sporadic PD, LRRK2 -associated PD ( LRRK2 PD), and GBA -associated PD ( GBA PD). Methods: We analyzed 7 years of motor, non-motor, and cognitive assessments and 5 years of dopamine transporter imaging along with baseline α-syn SAA results from 564 PPMI participants (n=332 sporadic PD, 162 LRRK2 PD, and 70 GBA PD) using linear mixed-effects models, adjusted for potential confounders, to test whether baseline α-syn SAA positivity (n=315 sporadic PD, 111 LRRK2 PD, and 66 GBA PD) was associated with PD progression. Results: While non-statistically significant, there was a trend towards faster motor decline in participants with α-syn SAA positive LRRK2 PD compared to those with α-syn SAA negative LRRK2 PD (MDS-UPDRS III points per year: 2.39 (95% confidence interval: 1.86 – 2.92) vs. 1.76 (0.93 – 2.60); difference=0.63 (−0.29 – 1.55, p=0.18). There was no difference in motor decline between α-syn SAA positive and α-syn SAA negative participants with sporadic PD (2.46 (2.20 – 2.72) vs. 2.39 (1.36 – 3.42); difference=0.07 (−0.99 – 1.12), p=0.90) or GBA PD (2.67 (1.91 – 3.44) vs. 2.40 (−0.18 – 4.99); difference=0.27 (−2.42 – 2.96), p=0.84). No statistically significant differences were seen in the progression of non-motor symptoms, cognition, or DAT imaging. Conclusions: We found no statistically significant associations between baseline α-syn seeding activity and PD progression among manifest patients in the PPMI cohort. Future studies are needed to further investigate relationships among baseline α-syn seeding activity, disease heterogeneity, disease stage, and PD progression.

1 May 2026 in Genes & Diseases
Verified
Journal Article
Open access
NZNingning Zhang
Ningning Zhang
SCSirui Chen
Sirui Chen
JJJialing Jiang
Jialing Jiang
HJHong Jiang
Hong Jiang
QWQing Wang
Qing Wang
XTXin Tian
Xin Tian
Epilepsy is a highly prevalent chronic central nervous system disorder that imposes substantial societal and economic burdens. Inconsistent associations of alcohol consumption, identified as a major global health risk factor, with epilepsy risk have been reported. The aim of the present study was to assess the relationship between alcohol use and epilepsy and to identify potential underlying mechanisms, with a particular focus on the role of neutrophil extracellular traps (NETs), using an integrated multiomic approach. We assessed the global risk of alcohol consumption for epilepsy using data from the Global Burden of Disease Study 2021, and we conducted a Mendelian randomization (MR) analysis to evaluate causality. Additionally, we employed machine learning algorithms and protein–protein interaction networks to identify key genes. Our results indicate that alcohol consumption significantly contributes to the risk of epilepsy, as confirmed by MR analysis (odds ratio = 1.30, 95% confidence interval 1.06–1.60; p = 0.011). Functional enrichment analysis revealed pathways related to NET formation, whereas machine learning identified key genes such as myeloperoxidase (MPO) and neutrophil elastase. Animal and molecular experiments confirmed that acute alcohol exposure increases the susceptibility to epileptic seizures, whereas the MPO inhibitor 4-aminobenzoic acid hydrazide showed therapeutic potential for alcohol-induced epilepsy. This study provides novel insights into the role of NETs in alcohol-induced epilepsy and highlights potential therapeutic targets, thereby contributing to the development of innovative treatment strategies for epilepsy prevention and management.